Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic gets a "positive surprise" from lead asset trial

By: TheNewswire.com

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  210.32
+1.76 (0.84%)
AAPL  273.32
+1.19 (0.44%)
AMD  213.00
-0.84 (-0.39%)
BAC  51.22
+0.81 (1.60%)
GOOG  311.67
+0.75 (0.24%)
META  649.19
+9.89 (1.55%)
MSFT  397.65
+8.65 (2.22%)
NVDA  195.22
+2.38 (1.23%)
ORCL  151.01
+4.87 (3.33%)
TSLA  413.89
+4.51 (1.10%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.